Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

Fig. 4

IL-17 F–expressing CD4+ T cells and brain volume changes in RRMS patients and HCs. Decreased percentage of IL-17 F–expressing CD4+ T cells from baseline to 6 months correlated with decreased whole brain volume from baseline to 6 months in RRMS patients treated with IFN β-1a SC tiw. HC healthy control; IFN interferon; IL interleukin; RRMS relapsing–remitting multiple sclerosis; SC subcutaneously; tiw three times weekly

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us